Joint involvement in inflammatory bowel disease: managing inflammation outside the digestive system

References

• Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut42, 387–381 (1998).
   PubMed Web of Science ®Google Scholar
• Braun J, Sieper J, Bollow M. Imaging of sacroiliitis. Clin. Rheumatol.19, 51–57 (2000).
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewé R et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann. Rheum. Dis.68, 777–783 (2009).
   PubMed Web of Science ®Google Scholar
• Palm O, Bernklev T, Moum B, Gran JT. Non-inflammatory joint pain in patients with inflammatory bowel disease is prevalent and has a significant impact on health related quality of life. J. Rheumatol.32, 1755–1759 (2005).
   PubMed Web of Science ®Google Scholar
• De Vos M, Cuvelier C, Mielants H, Veys E, Barbier F, Elewaut A. Ileocolonoscopy in seronegative spondylarthropathy. Gastroenterology96, 339–344 (1989).
   PubMed Web of Science ®Google Scholar
• De Vos M, Mielants H, Cuvelier C, Elewaut A, Veys E. Long-term evolution of gut inflammation in patients with spondylarthropathy. Gastroenterology110, 1696–1703 (1996).
   PubMed Web of Science ®Google Scholar
• Demetter P, Van Huysse JA, De Keyser F et al. Increase in lymphoid follicles and leukocyte adhesion molecules emphasizes a role for the gut in spondyloarthropathy pathogenesis. J. Pathol.198, 517–522 (2002).
   Google Scholar
• D’Inca R, Podswiadek M, Ferronato A et al. Articular manifestations in inflammatory bowel disease patients: a prospective study. Dig. Liver Dis.41, 565–569 (2009).
   PubMedGoogle Scholar
• De Vlam K, Mielants H, Cuvelier C et al. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J. Rheumatol.27, 2860–2865 (2000).
   PubMed Web of Science ®Google Scholar
• Peeters H, Vander Cruyssen B, Mielants H et al. Clinical and genetic factors associated with sacroilliitis in Crohn’s disease. J. Gastroenterol. Hepatol.23, 132–137 (2008).
   PubMed Web of Science ®Google Scholar
• Scott WW Jr, Fishman EK, Kuhlman JE et al. Computed tomography evaluation of the sacroiliac joints in Crohn disease. Radiologic/clinical correlation. Skeletal Radiol.19, 207–210 (1990).
   Google Scholar
• McEniff N, Eustace S, McCarthy C et al. Asymptomatic sacroiliitis in inflammatory bowel disease. Assessment by computed tomography. Clin. Imaging19, 258–262 (1995).
   Google Scholar
• Salvarani C, Fries W. Clinical futures and epidemiology of spondyloarthritides associated with inflammatory bowel disease. World J. Gastroenterol.15, 2449–2455 (2009).
   PubMed Web of Science ®Google Scholar
• van der Linden SM, Valkenburgh HA, de Jongh BM, Cats A. The risk of developing ankylosing spondylitis in HLAB27 positive individuals. A comparison of relatives of spondylitis patients with general population. Arthr. Rheum.27, 241–249 (1984).
   PubMed Web of Science ®Google Scholar
• Saraux A, Guillemin F, Guggenpuhl P et al. Prevalence of spondyloarthropathy in France: 2001. Ann. Rheum. Dis.64, 1431–1435 (2005).
   PubMed Web of Science ®Google Scholar
• Braun J, Bollow M, Remlinger G et al. Prevalence of spondyloarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum.41, 58–67 (1998).
   PubMed Web of Science ®Google Scholar
• Baeten D, De Keyser F. The histopathology of spondyloarthropathy (review). Curr. Mol. Med.4, 1–12 (2004).
   PubMed Web of Science ®Google Scholar
• Elewaut D, van Damme N, Baeten D et al. Enrichment of T cells carrying b7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy compared to rheumatoid arthritis. J. Rheumatol.25, 1932–1937 (1998).
   PubMed Web of Science ®Google Scholar
• Baeten D, Demetter P, Cuvelier CA et al. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J. Pathol.196, 343–350 (2002).
   PubMed Web of Science ®Google Scholar
• Demetter P, De Vos M, Van Huysse JA et al. Colon mucosa of patients both with spondyloarthritis and Crohn’s disease is enriched with macrophages expressing the scavenger receptor CD163. Ann. Rheum. Dis.64, 321–324 (2005).
   Google Scholar
• Jacques P, Mielants H, Coppieters K, De Vos M, Elewaut D. The intimate relationship between gut and joint in spondyloarthropathies (review). Curr. Opin. Rheumatol.19, 353–357 (2007).
   Google Scholar
• Hindryckx P, Serry G, Laukens D, Peeters H, De Vos M. Increased intestinal VEGF expression and mucosal vascularization in patients with spondylarthropathy. Gastroenterology136, A-559 (2009).
   Google Scholar
• Polzer K, Baeten D, Soleiman A et al. Tumour necrosis factor blockade increases lymphangiogenesis in murine and human arthritis joints. Ann. Rheum. Dis.67, 1610–1616 (2008).
   PubMed Web of Science ®Google Scholar
• Schett G. Joint remodelling in inflammatory diseases. Ann. Rheum. Dis.66(Suppl. 3), iii42–iii44 (2007).
   Google Scholar
• Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity10, 387–398 (1999).
   PubMed Web of Science ®Google Scholar
• Armaka M, Apostolaki M, Jacques P, Kontoyiannis DL, Elewaut D, Kollias G. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J. Exp. Med.205, 331–337 (2008).
   Web of Science ®Google Scholar
• Kontoyiannis D, Boulougouris G, Manoloukos M et al. Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn’s-like inflammatory bowel disease. J. Exp. Med.196, 1563–1574 (2002).
   PubMed Web of Science ®Google Scholar
• Taurog JD, Maika SD, Simmons WA, Breban M, Hammer RE. Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression. J. Immunol.150, 4168–4178 (1993).
   PubMed Web of Science ®Google Scholar
• Rath HC, Wilson KH, Sartor RB. Differential induction of colitis and gastritis in HLA B27 transgene rats selectively colonized with Bacteroides vulgatus and Eschericia coli. Infect. Immunol.67, 2969–2974 (1999).
   PubMed Web of Science ®Google Scholar
• Rath HC, Schultz M, Freitag R et al. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect. Immun.69, 2277–2285 (2001).
   PubMed Web of Science ®Google Scholar
• Hacquard-Bouder C, Falgarone G, Bosquet A et al. Alteration of antigen-independent immunologic synapse formation between dendritic cells from HLA-B27 transgenic rats and CD4+ T cells: selective impairment of costimulatory molecules engagement by mature HLA-B27. Arthritis Rheum.56, 1478–1489 (2007).
   Google Scholar
• Fert I, Glatigny S, Poulain C et al. Correlation between dendritic cell functional defect and spondylarthritis phenotypes in HLA-B27/HUMAN β2-microglobulin-transgenic rat lines. Arthritis Rheum.58, 3425–3429 (2008).
   PubMedGoogle Scholar
• Turner MJ, Delay ML, Bai S, Klenk E, Colbert RA. HLA-B27 up-regulation causes accumulation of misfolded heavy chains and correlates with the magnitude of the unfolded protein response in transgenic rats: implications for the pathogenesis of spondylarthritis-like disease. Arthritis Rheum.56, 215–223 (2007).
   PubMed Web of Science ®Google Scholar
• Tran TM, Dorris ML, Satumtira N et al. Additional human β2-microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in male HLA-B27 -transgenic rats. Arthritis Rheum.54, 1317–1327 (2006).
   PubMed Web of Science ®Google Scholar
• Reveille JD. Recent studies on the genetic basis of ankylosing spondylitis (review). Curr. Rheumatol. Rep.11, 340–348 (2009).
   PubMedGoogle Scholar
• Barrett JC, Hansoul S, Nicolae DL et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat. Genet.29, 175 (2008).
   Google Scholar
• Manel N, Unutmaz D, Littman DR. The differentiation of human Th17 cells require transforming growth factor-β and induction of the nuclear receptor RORg. Nat. Immunol.9, 641–649 (2008).
   PubMed Web of Science ®Google Scholar
• Yang L, Anderson DE, Baecher-Allan C et al. IL-21 and TGF-β are required for differentiation of human Th17 cells. Nature454, 350–352 (2008).
   PubMed Web of Science ®Google Scholar
• Brand S. Crohn’s disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s disease. Gut58, 1152–1167 (2009).
   PubMed Web of Science ®Google Scholar
• Schmechel S, Konrad A, Diegelman J et al. Linking genetic susceptibility to Crohn’s disease with Th17 cell function: IL-22 serum levels are increased in Crohn’s disease and correlate with disease activity and IL23R genotype status. Inflamm. Bowel Dis.14, 204–212 (2008).
   PubMed Web of Science ®Google Scholar
• Ciccia F, Bombardieri M, Principato A et al. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum.60, 955–965 (2009).
   PubMed Web of Science ®Google Scholar
• Melis L, Vandooren B, Kruithof E et al. Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann. Rheum. Dis. DOI: 10.1136/ard.2009.107649 (2009) (Epub ahead of print).
   Google Scholar
• Laukens D, Peeters H, Marichal D et al.CARD15 gene polymorphisms in patients with spondyloarthorpathies identify a specific phenotype previously related to Crohn’s disease. Ann. Rheum. Dis.64, 930–935 (2005).
   PubMed Web of Science ®Google Scholar
• Micelli-Richard C, Zouali H, Lesage S et al. CARD15/NOD2 analyses in spondyloarthropathy. Arthritis Rheum.46, 1405–1406 (2002).
   Google Scholar
• Craene AM, Bradbury L, Van Heel DA et al. Role of NOD2 variants in spondyloarthritis. Arthritis Rheum.46, 1629–1633 (2002).
   Google Scholar
• Laukens D, Peeters H, Cruyssen BV et al. Altered gut transcriptome in spondyloarthropathy. Ann. Rheum. Dis.65, 1293–1300 (2006).
   Google Scholar
• Georges M, Laukens D, Libioulle C et al. Evidence for significant overlap between common risk variants for Crohn’s disease and ankylosing spondylitis. Acta Gastroenterol. Belg.72, 103 (2009).
   Google Scholar
• Forrest K, Symmons D, Foster P. Systematic review: is ingestion of paracetamol or non-steroidal antiinflammatory drugs associated with exacerbations of inflammatory bowel disease ? Aliment Pharmacol. Ther.20, 1035–1043 (2004).
   PubMed Web of Science ®Google Scholar
• Feagins LA, Cryer BL. Do non-steroidal anti-inflammatory drugs cause exacerbations of inflammatory bowel disease? Dig. Dis. Sci.55(2), 226–232 (2009).
   Google Scholar
• Kefalakes H, Stylianedes TJ, Amanakis G, Kolios G. Exacerbation of inflammatory bowel disease associated with the use of nonsteroidal antiinflammatory drugs: myth or reality? Eur. J. Clin. Pharmacol.65, 963–970 (2009).
   PubMed Web of Science ®Google Scholar
• Singh S, Graff LA, Bernstein CN. Do NSAIDs, antibiotics, infections or stress trigger flares in IBD? Am. J. Gastroenterol.104, 1298–1313 (2009).
   PubMed Web of Science ®Google Scholar
• Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case–control study. Am. J. Gastroenterol.95, 1949–1954 (2000).
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Smale S, Premchand P et al. Prevalence and mechanism of non-steroidal antiinflammatory drug induced clinical relapse in patients with IBD. Clin. Gastroenterol. Hepatol.4, 196–202 (2006).
   PubMed Web of Science ®Google Scholar
• Bonner GF, Fakhri A, Vennamanen SR. A long-term cohort study of non-steroidal antiinflammatory drug use and disease activity in outpatients with inflammatory bowel diseases. Inflamm. Bowel Dis.10, 751–757 (2004).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Stenson WF, Brynskov J et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomised placebo controlled pilot study. Clin. Gastroenterol. Hepatol.4, 203–211 (2006).
   PubMed Web of Science ®Google Scholar
• El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective COX-2 inhibitor in inflammatory bowel diseases. Am. J. Gastroenterol.101, 311–317 (2006).
   PubMed Web of Science ®Google Scholar
• Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann. Rheum. Dis.65, 423–432 (2006).
   PubMed Web of Science ®Google Scholar
• Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H. Crohn’s disease associated with spondyloarthropathy: effect of TNF-α blockade with infliximab on articular symptoms. Lancet356, 1821–1822 (2000).
   PubMed Web of Science ®Google Scholar
• Generini S, Giacomelli R, Fedi R et al. Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on the efficacy of inducing and maintaining remission at musculoskeletal and gut manifestations. Ann. Rheum. Dis.63, 1664–1669 (2004).
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Listing J et al. Differences in the incidence of flares or new onset of inflammatory bowel disease in patients with ankylosing spondylitis exposed to therapy with anti-TNF agents. Arthritis Rheum.57, 639–647 (2007).
   PubMed Web of Science ®Google Scholar
• Hindryckx P, Waeytens A, Laukens D, Peeters H, Van Huysse J, De Vos M. Absence of placental growth factor aggravates DSS-induced acute colonic injury. J. Crohns Colitis3(1), S124–S125 (2009).
   Google Scholar
• Hindryckx P, Laukens D, Jacques P, Peeters H, Vandenabeele P, De Vos M. Protective effect of prolyl hydroxylase inhibition on tumor necrosis factor – induced intestinal pathology. Presented at: GASTRO 2009 UEGW/WCOG. London, UK, 21–25 November 2009.
   Google Scholar
• Mannon PJ, Fuss IJ, Mayer L et al. Anti-interleukin 12 antibody for active Crohn’s disease. N. Engl. J. Med.351, 2069–2079 (2004).
   PubMed Web of Science ®Google Scholar
• Burakoff R, Barish CF, Riff D et al. A Phase 1/2 trial of STA 5326, an oral interleukin 12/23 inhibitor in patients with active moderate to severe Crohn’s disease. Inflamm. Bowel Dis.12, 558–565 (2006).
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Menter A, Mendelsohn A et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet373, 633–640 (2009).
   PubMed Web of Science ®Google Scholar
• Toedter GP, Blank M, Lang Y, Chen D, Sandborn WJ, de Villiers WJ. Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn’s disease. Am. J. Gastroenterol.104, 2768–2773 (2009).
   PubMed Web of Science ®Google Scholar
• Canete JD, Celis R, Hernandez MV, Pablos JL, Sanmarti R. Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis. Ann. Rheum. Dis. DOI: 10.1136/ard.2009.113233 (2009).
   Google Scholar
• Kaser A, Lee AH, Franke A et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell134, 743–756 (2008).
   PubMed Web of Science ®Google Scholar
• Kaser A, Blumberg RS. Endoplasmic reticulum stress in the intestinal epithelium and inflammatory bowel disease. Semin. Immunol.21, 156–163 (2009).
   PubMedGoogle Scholar
• Todd DJ, Lee AH, Glimcher LA et al. The endoplasmatic reticulum stress response in immunity and autoimmunity (review). Nat. Rev.8, 663–674 (2008).
   Google Scholar